Boston Scientific (NYSE:BSX), founded in 1979 by John Abele and Peter Nicholas, is a global developer, manufacturer and marketer of medical devices designed to improve the health of patients around the world. Headquartered in Marlborough, Massachusetts, the company has built its reputation on delivering innovative, minimally invasive solutions that address a wide range of medical conditions. Over its history, Boston Scientific has grown through a combination of organic R&D investments and strategic acquisitions, expanding its portfolio and geographic reach.
The company’s core business activities center on interventional medical specialties, including cardiovascular, rhythm management, endoscopy, urology and pelvic health, and neuromodulation. Its product offerings include stents and catheters for treating coronary artery disease, implantable cardioverter-defibrillators and pacemakers for cardiac rhythm disorders, advanced endoscopy systems for gastrointestinal diagnostics and treatment, as well as devices for urological and pelvic floor disorders. Boston Scientific continually seeks to enhance patient outcomes by integrating digital health technologies and novel materials into its device designs.
Operating in more than 100 countries, Boston Scientific maintains research and development centers, manufacturing facilities and commercial operations across North America, Europe, Asia and Latin America. The company collaborates with clinicians, academic institutions and technology partners to drive clinical evidence generation and support market adoption of its therapies. With a focus on innovation, quality and patient safety, Boston Scientific aims to advance the practice of less-invasive medical care and deliver long-term value to healthcare providers and patients alike.
